04 Jul 2013 Posted in ABPI statement By Press Office
"Key to this will be building stronger partnerships with the pharmaceutical industry to deliver improved patient care whilst saving the healthcare system money.
“Innovation in medicines driven by the research of the pharmaceutical industry has underpinned the ability of the NHS to deliver care and treat many once life threatening diseases, from coronary heart disease, diabetes, serious mental illness, HIV and many cancers, with minimal expense. To face the future challenges the NHS must embrace medical innovation to meet the needs of patients whilst maintaining the affordability of the healthcare system.
"The launch of Genomics England is welcome news – I am excited about what we can achieve through regular DNA sequencing throughout the National Health Service. This important initiative will help the life sciences sector better understand the genomic make-up of patient populations which will in turn further our understanding of disease and the way we develop medicines. Being able to link genomics with health records will strengthen the UK’s position as a leader in this field. It will be key to driving further research into stratified medicines – treatments tailored to those most likely to respond – and ultimately will help scientists and pharmaceutical companies create more targeted medicines to benefit patients."
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.